2024-03-29T11:02:07Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_EFE5644700C1
2024-03-23T03:11:08Z
serval:BIB_EFE5644700C1
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
10.1136/annrheumdis-2013-203348
23532441
000316826300002
Furst
D.E.
author
Keystone
E.C.
author
So
A.K.
author
Braun
J.
author
Breedveld
F.C.
author
Burmester
G.R.
author
De Benedetti
F.
author
Dörner
T.
author
Emery
P.
author
Fleischmann
R.
author
Gibofsky
A.
author
Kalden
J.R.
author
Kavanaugh
A.
author
Kirkham
B.
author
Mease
P.
author
Rubbert-Roth
A.
author
Sieper
J.
author
Singer
N.G.
author
Smolen
J.S.
author
Van Riel
P.L.
author
Weisman
M.H.
author
Winthrop
K.L.
author
article
review
2013
Annals of the Rheumatic Diseases
1468-2060
0003-4967
journal
72
Suppl. 2
ii2-i34
Antibodies, Monoclonal, Humanized/adverse effects
Antibodies, Monoclonal, Humanized/therapeutic use
Antirheumatic Agents/adverse effects
Antirheumatic Agents/therapeutic use
Female
Humans
Immunoconjugates/adverse effects
Immunoconjugates/therapeutic use
Immunosuppressive Agents/adverse effects
Immunosuppressive Agents/therapeutic use
Male
Polyethylene Glycols/adverse effects
Polyethylene Glycols/therapeutic use
Pregnancy
Rheumatic Diseases/complications
Rheumatic Diseases/drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Urate Oxidase/adverse effects
Urate Oxidase/therapeutic use
eng
60_published
Publication types: Consensus Development Conference ; Journal ArticlePublication Status: ppublish